A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

Exclusion Criteria

• •Non-small cell lung cancer (NSCLC) participants with a diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements.
• •Melanoma participants with ocular, mucosal, or conjunctival melanoma.
• •Renal Cell Carcinoma (RCC) participants who have had major surgery, other than nephrectomy, within 12 weeks before randomization.
• •Has received prior radiotherapy for RCC.
• •RCC participants who have residual thrombus post nephrectomy in the vena renalis or vena cava.
• •Has received prior therapy with an anti-programmed cell death 1 protein (PD-1), PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137).
• •Has received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization.
• •Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
• •Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids.
• •Received prior systemic anticancer therapy for their metastatic NSCLC. Note: Prior treatment with neoadjuvant or adjuvant therapy for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC.
• •Received radiation therapy to the lung that is \>30 Gray within 6 months of start of study intervention.
• •Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.
• •Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication.
• •Has known additional malignancy that is progressing or has required active treatment within the past 3 years.
• •Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
• •Has active autoimmune disease that has required systemic treatment in the past 2 years.
• •Has history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
• •Has active infection requiring systemic therapy.
• •HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
• •Has history of allogeneic tissue/solid organ transplant corticosteroids.
• •Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
• •Has not adequately recovered from major surgery or have ongoing surgical complications.